Eli Lilly was the first pharmaceutical company to exceed a $500 billion market capitalization.
Eli Lilly passed the $500 billion valuation level in 2024 as investors responded to strong demand and expectations for its diabetes and obesity medicines. The company’s growth was closely associated with tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management in the United States.
Founded in 1876 by Colonel Eli Lilly, the company has developed medicines across diabetes, oncology, immunology, neuroscience, and other fields. Its history includes the production of insulin and the development of widely used medicines such as Prozac.
Market capitalization reflects investor expectations as well as present earnings. Drug-company valuations can move sharply when clinical-trial results, regulatory decisions, patent changes, or prescription trends alter expectations. The milestone should not be confused with the value of all global healthcare companies or with annual pharmaceutical sales.